We are a group of motivated immunologists and oncologists committed to delivering the power of cytokines to patients.
Founded in 2017 by leading experts in the field of immunotherapy, Anaveon is a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction.
Our goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.
Our approach
We are exploiting the power of cytokines to orchestrate immune responses by using protein engineering to create safe and effective treatments for a variety of serious diseases.
IL-2 Cancer Immunotherapy
Our first program going into clinical trials is ANV419, a selective interleukin-2 (IL-2) receptor agonist – a type of protein that can enhance a patient’s immune system in order to target and defeat tumors.
Our Immunotherapy Pipeline
Our pipeline includes additional programs that leverage targeted cytokines for a range of immune-mediated diseases.
Years of Experience
Million CHF Funding
Growing team
LATEST NEWS
05
June
2023
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual Meeting
03
June
2023
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
18
April
2023
23
March
2023
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
16
March
2023
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
Our dedicated team of experts has decades of experience in immunology, oncology and drug design. We use our deep knowledge to deliver novel drugs that address unmet medical needs.
About us
We are committed to developing treatments that benefit patients.
Science
We are developing an IL-2 immunotherapy for cancer.
Team
We are driven by the urgency of patients.
Investors
&
Partners
We are backed by more than 146 million CHF of funding.